Introduction:

Screening has greatly reduced the mortality of cervical cancer, but the treatment of metastatic disease remains ineffective. Now, vaccines against the major cause of cervical cancer, the human papillomavirus, may provide an effective preventative treatment for the disease, but is Western society ready for a cure that requires school age girls to be immunized against a venereal disease?

Scope:

* Overview of cervical cancer including etiology, epidemiology and primary treatment patterns by disease stage 

* Review of the currently used drugs in cervical cancer and the opportunities manufacturers can exploit in underserved sections of this population 

* Analysis of the impact screening has had upon cervical cancer mortality and the likely impact of new technologies on patient presentation patterns 

* Overview of the development of preventative vaccines for cervical cancer and an analysis of the markets in which they are most likely to be used 

Report Highlights:

Drug therapy for metastatic cervical cancer is ineffective. Few and short-lived responses to currently used regimens have produced a market entry indication which may provide Fast-Track and Orphan Drug designation. 

The use of cisplatin as a radiosensitizer in locally advanced disease is firmly established. However, know radiosensitizers, such as gemcitabine, may offer greater efficacy or lower toxicity. 

The introduction of mass vaccination against HPV, the primary cause of cervical cancer, poses a social dilemma. Is society ready to vaccinate its children against venereal disease and what steps can vaccine manufacturers take to maximize uptake of their product? 

Reasons to Purchase:

* Identify the underserved drug-treatable populations for cervical cancer and the regulatory benefits these indications provide 

* Evaluate the patient potential of the cervical cancer market in the face of early-stage diagnosis provided by new screening t technologies 

* Define the potential for human papillomavirus vaccines and the marketing strategies that marketers should be employing 

Publisher: Datamonitor Oncology Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a265